LTT Biopharma Interstitial Pneumonia Drug Obtains MHLW Orphan Status
This article was originally published in PharmAsia News
Executive Summary
The First Committee on New Drugs at the Ministry of Health, Labor and Welfare June 4 granted orphan drug status to LTT Biopharma's midismase (recombinant) for interstitial pneumonia. Midismase is a lecithinized superoxide dismutase (PC-SOD) that is in Phase II clinical trials in Japan. Tokyo-based LTT specializes in developing new drug delivery systems, and the orphan status will accelerate the regulatory approval process and help obtain financial assistance. (Click here for more - Japanese language)"LTT Biopharma Shares Jump Due To Obtaining Orphan Drug Status For New Drug" - Search China News (6/7/2010)
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.